Article preview reprinted from Start-Up - October 2008
Find out how the difficulties on Wall Street are washing down to the private market causing medical device VCs to reconsider investment strategies and exiting routes.
Device VCs not Immune to Crisis
Article preview reprinted from Start-Up - October 2008
Conventional wisdom has always suggested that the public markets have little or no immediate impact on how venture investors operate. After all, venture capital investors—particularly those investing in the life sciences—are looking six to eight years down the road at a potential return from an investment made today. So it makes no sense to measure the value of an investment based on the headlines of the Wall Street Journal.
But conventional wisdom has a shelf life. Today, venture capital investors increasingly share the fate of the public markets. The business news of today may not immediately impact the investments these firms are making, but a financial storm this powerful is being felt everywhere.
Purchase this 3728-word article online as a PDF for just $125 and receive it immediately via email. Questions? Call (800) 332-2181. 100% Satisfaction Guaranteed.
Companies mentioned in this article:
Boston Scientific Corp.
CryoCath Technologies Inc.
Medtronic Inc.
NuVasive Inc.
Volcano Corp.
Wright Medical Group Inc.
ev3 Inc.
START-UP: No publication reviews leading edge companies and technology better than START-UP. Each issue of START-UP profiles the most important new product companies, identifies the hottest technology areas, reviews funds flowing into private companies and investment trends, and reports on university tech transfer licensing. Industries covered: pharmaceuticals, biotechnology, medical equipment & devices, and in vitro diagnostics. Subscribe to START-UP.
